Stock CYP CYNATA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cynata Therapeutics Limited

Equities

CYP

AU000000CYP7

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 11:14:06 2024-06-04 pm EDT 		5-day change 1st Jan Change
0.31 AUD -6.06% Intraday chart for Cynata Therapeutics Limited -4.62% +148.00%
Apr. 08 Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial CI
Apr. 08 Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial MT

Valuation

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Capitalization 1 126.8 71.45 22.45 59.28 - -
Enterprise Value (EV) 1 119.9 57.8 22.45 32.58 35.48 43.08
P/E ratio -14.7 x -17.5 x -1.27 x -6.35 x -10.3 x -19.4 x
Yield - - - - - -
Capitalization / Revenue 80.8 x 9.99 x - 25.8 x 65.9 x 8.23 x
EV / Revenue 76.4 x 8.08 x - 14.2 x 39.4 x 5.98 x
EV / EBITDA -14.6 x - - -3.5 x -4.33 x -9.79 x
EV / FCF -17.7 x - - -3.54 x -4.38 x -9.79 x
FCF Yield -5.64% - - -28.2% -22.8% -10.2%
Price to Book - - - 3.3 x 3.3 x -
Nbr of stocks (in thousands) 101,885 117,124 179,632 179,632 - -
Reference price 2 1.245 0.6100 0.1250 0.3300 0.3300 0.3300
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Net sales 1 1.569 7.154 - 2.3 0.9 7.2
EBITDA 1 -8.192 - - -9.3 -8.2 -4.4
EBIT 1 -8.472 -3.639 - -9.6 -8.5 -4.7
Operating Margin -539.94% -50.87% - -417.39% -944.44% -65.28%
Earnings before Tax (EBT) 1 -8.472 -3.639 - -9.4 -8.3 -4.6
Net income 1 -8.472 -3.639 -14.28 -9.4 -8.3 -4.6
Net margin -539.94% -50.87% - -408.7% -922.22% -63.89%
EPS 2 -0.0848 -0.0348 -0.0984 -0.0520 -0.0320 -0.0170
Free Cash Flow 1 -6.759 - - -9.2 -8.1 -4.4
FCF margin -430.76% - - -400% -900% -61.11%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 6.98 13.6 - 26.7 23.8 16.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -6.76 - - -9.2 -8.1 -4.4
ROE (net income / shareholders' equity) -77.2% - - - - -
ROA (Net income/ Total Assets) -59.7% - - - - -
Assets 1 14.19 - - - - -
Book Value Per Share 2 - - - 0.1000 0.1000 -
Cash Flow per Share 2 - - - -0.0500 -0.0300 -0.0200
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CYNATA THERAPEUTICS LIMITED Stock Cynata Therapeutics Limited
+148.00% 38.41M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.73% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.04% 107B
BIONTECH SE Stock BioNTech SE
-5.80% 24.82B
ARGENX SE Stock argenx SE
+1.69% 22.48B
GENMAB A/S Stock Genmab A/S
-10.09% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.52% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.00% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.18% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.18% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYP Stock
  4. Financials Cynata Therapeutics Limited